Tenaya Therapeutics, Inc. TNYA

TNYA Company Overview

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering therapies for heart disease, with a primary emphasis on genetic and rare cardiomyopathies. The company operates within the biotechnology and cardiovascular therapeutics industries and develops multiple therapeutic modalities, including gene therapy, cell therapy, and precision medicine approaches. Its core objective is to address the underlying molecular causes of heart disease rather than only managing symptoms, positioning the company within the emerging field of disease-modifying cardiovascular therapeutics.

The company’s principal programs have focused on inherited forms of cardiomyopathy such as arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), and heart failure-related conditions. Revenue generation has historically been limited because Tenaya remains primarily in the research and clinical development stage, with funding derived largely from public equity financing, collaborations, and investment capital rather than commercialized products. Founded in 2016, Tenaya Therapeutics evolved from advances in cardiovascular genetics and regenerative medicine research developed by scientific founders associated with major academic institutions and biotechnology research programs.